Oxurion NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurions product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.

Oxurion NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxurion NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxurion NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Oxurion Enters into Research Agreement with Beta Therapeutics 11
ThromboGenics Forms Joint Venture with VIB 12
Licensing Agreements 13
Oncurious Enters into Licensing Agreement with VIB 13
ThromboGenics Enters into Licensing Agreement with Galapagos 14
ThromboGenics Expands Licensing Agreement with Bicycle Therapeutics 15
ThromboGenics Enters into Licensing Agreement with Grifols 16
Equity Offering 17
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 17
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 18
Oxurion NV - Key Competitors 20
Oxurion NV - Key Employees 21
Oxurion NV - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Sep 06, 2018: ThromboGenics business update H1 2018 23
May 09, 2018: ThromboGenics Business Update - Q1 2018 25
Mar 15, 2018: ThromboGenics Business Update - FY 2017 27
Sep 07, 2017: ThromboGenics Business Update - H1 2017 32
Mar 16, 2017: ThromboGenics Business Update - FY 2016 36
Corporate Communications 40
Oct 29, 2018: Oxurion names Adrienne Graves as board director 40
Nov 08, 2017: ThromboGenics Strengthens Leadership Team 41
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 42
Product News 43
04/20/2017: Thrombogenics Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 43
04/04/2018: ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 44
Product Approvals 45
Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 45
Clinical Trials 46
Apr 27, 2018: ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME 46
Apr 06, 2018: ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema 47
Oct 09, 2017: ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR 48
Sep 27, 2017: ThromboGenics: ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting 49
May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 50
Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 51
Other Significant Developments 52
Sep 03, 2018: ThromboGenics becomes Oxurion 52
Jun 27, 2018: ThromboGenics Plans Name Change to Oxurion 53
Jun 21, 2018: ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC 54
Oct 20, 2017: ThromboGenics Business Update - Q3 2017 55
May 11, 2017: ThromboGenics Business Update Q1 2017 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List Of Tables


Oxurion NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Deals By Therapy Area, 2012 to YTD 2018 9
Oxurion NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxurion Enters into Research Agreement with Beta Therapeutics 11
ThromboGenics Forms Joint Venture with VIB 12
Oncurious Enters into Licensing Agreement with VIB 13
ThromboGenics Enters into Licensing Agreement with Galapagos 14
ThromboGenics Expands Licensing Agreement with Bicycle Therapeutics 15
ThromboGenics Enters into Licensing Agreement with Grifols 16
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 17
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 18
Oxurion NV, Key Competitors 20
Oxurion NV, Key Employees 21
Oxurion NV, Other Locations 22
Oxurion NV, Subsidiaries 22

List Of Figures


Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oxurion NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is

USD 250 View Report

ThromboGenics NV (THR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in

USD 250 View Report

ThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review

ThromboGenics NV (THR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available